MA59295A1 - Lieurs sans trace et conjugués protéiques associés - Google Patents
Lieurs sans trace et conjugués protéiques associésInfo
- Publication number
- MA59295A1 MA59295A1 MA59295A MA59295A MA59295A1 MA 59295 A1 MA59295 A1 MA 59295A1 MA 59295 A MA59295 A MA 59295A MA 59295 A MA59295 A MA 59295A MA 59295 A1 MA59295 A1 MA 59295A1
- Authority
- MA
- Morocco
- Prior art keywords
- protein conjugates
- compounds
- related protein
- traceless
- traceless linkers
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne des composés, des composés comprenant des lieurs sans trace, des conjugués protéiques associés, et des compositions associées. L'invention concerne également des méthodes de traitement de maladies, de troubles et d'états, et/ou la gestion de leurs symptômes, associés à des maladies inflammatoires et des troubles auto-immuns associés en outre au récepteur des glucocorticoïdes, à la liaison aux glucocorticoïdes et/ou à la signalisation des récepteurs des glucocorticoïdes, comprenant l'administration des composés ou de charges utiles par l'intermédiaire de charges utiles de lieurs sans trace, et des conjugués protéiques associés.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/243,020 US20190209702A1 (en) | 2018-01-08 | 2019-01-08 | Steroids and antibody-conjugates thereof |
US201962872229P | 2019-07-09 | 2019-07-09 | |
US201962937721P | 2019-11-19 | 2019-11-19 | |
PCT/US2020/012798 WO2020146541A2 (fr) | 2019-01-08 | 2020-01-08 | Lieurs sans trace et conjugués protéiques associés |
Publications (1)
Publication Number | Publication Date |
---|---|
MA59295A1 true MA59295A1 (fr) | 2023-07-31 |
Family
ID=71521936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53772A MA53772B1 (fr) | 2019-01-08 | 2020-01-08 | Lieurs sans trace et conjugués protéiques associés |
MA59295A MA59295A1 (fr) | 2019-01-08 | 2020-01-08 | Lieurs sans trace et conjugués protéiques associés |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53772A MA53772B1 (fr) | 2019-01-08 | 2020-01-08 | Lieurs sans trace et conjugués protéiques associés |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3908323A2 (fr) |
JP (1) | JP2022517767A (fr) |
KR (1) | KR20210114008A (fr) |
CN (1) | CN113905767A (fr) |
AU (1) | AU2020205662A1 (fr) |
BR (1) | BR112021013464A2 (fr) |
CA (1) | CA3125998A1 (fr) |
CL (1) | CL2021001790A1 (fr) |
CO (1) | CO2021010315A2 (fr) |
IL (1) | IL284673A (fr) |
MA (2) | MA53772B1 (fr) |
MX (1) | MX2021008114A (fr) |
SG (1) | SG11202107212QA (fr) |
WO (1) | WO2020146541A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018089373A2 (fr) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Stéroïdes et leurs conjugués protéiques |
CA3063871A1 (fr) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Conjugues medicamenteux proteiques a base de cyclodextrine |
KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023079362A1 (fr) * | 2021-11-03 | 2023-05-11 | Ripple Therapeutics Corporation | Compositions aptes à être traitées et leur utilisation |
WO2023137026A1 (fr) | 2022-01-12 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | Conjugués protéine-médicament comprenant des analogues de camptothécine et procédés d'utilisation associés |
TW202340252A (zh) * | 2022-01-29 | 2023-10-16 | 大陸商上海盛迪醫藥有限公司 | 糖皮質激素的藥物偶聯物 |
WO2024118785A2 (fr) | 2022-11-30 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Agonistes de tlr7 et conjugués anticorps-médicament associés |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
KR101200133B1 (ko) | 2004-06-01 | 2012-11-13 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
EP1817341A2 (fr) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Anticorps et immunoconjugues mis au point |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2008122039A2 (fr) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molécules d'anticorps hybrides médiées par la sélénocystéine |
CA2687178C (fr) | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Supports polymeres pour immunohistochimie et hybridation in situ |
BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
WO2012005982A2 (fr) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Rapporteur pour une terminaison par la arn polymérase ii |
WO2012166559A1 (fr) | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CA2850373C (fr) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines et conjugues cibles |
EP3309162A1 (fr) | 2011-10-14 | 2018-04-18 | Seattle Genetics, Inc. | Conjugues cibles des pyrrolobenzodiazepines |
AU2012322933B2 (en) | 2011-10-14 | 2017-02-02 | Medimmune Limited | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
EP2751111B1 (fr) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Dérivés asymmetriques de bis-(5H-pyrrolo[2,1-c][1,4]benzodiazépin-5-one) pour le traitement de maladies prolifératives ou auto-immunes |
WO2013068874A1 (fr) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Conjugués anticorps-médicament |
RS64329B1 (sr) | 2012-10-23 | 2023-08-31 | Synaffix Bv | Modifikovano antitelo, konjugat antitela i postupak za njihovo pripremanje |
WO2014202775A1 (fr) * | 2013-06-21 | 2014-12-24 | Innate Pharma | Conjugaison enzymatique de polypeptides |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
ES2859648T3 (es) * | 2014-04-10 | 2021-10-04 | Daiichi Sankyo Co Ltd | Conjugado anticuerpo-fármaco anti-HER3 |
AU2017274442B2 (en) * | 2016-06-02 | 2021-08-19 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
JP7078609B2 (ja) | 2016-09-23 | 2022-05-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗steap2抗体、抗体-薬物複合体、およびsteap2とcd3を結合する二重特異性抗原結合分子、ならびにそれらの使用 |
JP2020520926A (ja) * | 2017-05-18 | 2020-07-16 | レゲネロン ファーマシューティカルス,インコーポレーテッド | ビス−オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
CA3063871A1 (fr) * | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Conjugues medicamenteux proteiques a base de cyclodextrine |
CN109106951A (zh) * | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
CN108853514B (zh) * | 2017-08-18 | 2022-07-22 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
AU2019205542A1 (en) * | 2018-01-08 | 2020-07-16 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
US20190343221A1 (en) | 2018-05-08 | 2019-11-14 | Nike, Inc. | Bonding to polyolefin plates and articles of footwear formed therefrom |
KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
-
2020
- 2020-01-08 CA CA3125998A patent/CA3125998A1/fr active Pending
- 2020-01-08 WO PCT/US2020/012798 patent/WO2020146541A2/fr unknown
- 2020-01-08 MX MX2021008114A patent/MX2021008114A/es unknown
- 2020-01-08 SG SG11202107212QA patent/SG11202107212QA/en unknown
- 2020-01-08 EP EP20702563.6A patent/EP3908323A2/fr active Pending
- 2020-01-08 MA MA53772A patent/MA53772B1/fr unknown
- 2020-01-08 JP JP2021539640A patent/JP2022517767A/ja active Pending
- 2020-01-08 AU AU2020205662A patent/AU2020205662A1/en active Pending
- 2020-01-08 KR KR1020217024347A patent/KR20210114008A/ko unknown
- 2020-01-08 MA MA59295A patent/MA59295A1/fr unknown
- 2020-01-08 CN CN202080019317.3A patent/CN113905767A/zh active Pending
- 2020-01-08 BR BR112021013464-6A patent/BR112021013464A2/pt unknown
-
2021
- 2021-07-06 CL CL2021001790A patent/CL2021001790A1/es unknown
- 2021-07-07 IL IL284673A patent/IL284673A/en unknown
- 2021-08-04 CO CONC2021/0010315A patent/CO2021010315A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022517767A (ja) | 2022-03-10 |
CL2021001790A1 (es) | 2022-07-01 |
BR112021013464A2 (pt) | 2021-09-21 |
MA53772B1 (fr) | 2023-08-31 |
CA3125998A1 (fr) | 2020-07-16 |
MA53772A1 (fr) | 2022-10-31 |
EP3908323A2 (fr) | 2021-11-17 |
WO2020146541A2 (fr) | 2020-07-16 |
KR20210114008A (ko) | 2021-09-17 |
CO2021010315A2 (es) | 2021-08-19 |
AU2020205662A1 (en) | 2021-07-22 |
WO2020146541A3 (fr) | 2020-08-13 |
CN113905767A (zh) | 2022-01-07 |
SG11202107212QA (en) | 2021-07-29 |
MX2021008114A (es) | 2021-08-05 |
IL284673A (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA59295A1 (fr) | Lieurs sans trace et conjugués protéiques associés | |
MA47392A1 (fr) | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques | |
MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
MA31016B1 (fr) | Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine. | |
MA30337B1 (fr) | Anticorps | |
MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
MA34517B1 (fr) | Promédicaments comprenant un conjugué exendine-lieur | |
MA40041A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA32131B1 (fr) | Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine | |
MA31821B1 (fr) | Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations | |
MA45125B1 (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA31403B1 (fr) | Polypeptides, domaines variables d'anticorps et antagonistes | |
MA53455A1 (fr) | Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr | |
MA29931B1 (fr) | Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap) | |
MA34287B1 (fr) | Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6) | |
MA33534B1 (fr) | Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine | |
MA31437B1 (fr) | Polypeptides, domaines variables d'anticorps et antagonistes | |
BRPI0514259A (pt) | proteìna de fusão de domìnio de ligação | |
WO2004091510A3 (fr) | Anticorps il-9 recombinants et leurs utilisations | |
MA29427B1 (fr) | Antagonistes et leurs methodes d'utilisation | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
MA29723B1 (fr) | Composes | |
MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
MA33758B1 (fr) | Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes | |
MA49947B1 (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |